Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.Read More
Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership
